Literature DB >> 22354567

Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.

Sujal Ghosh1, Friedhelm R Schuster, Vera Binder, Tim Niehues, Stephan E Baldus, Peter Seiffert, Hans-Jürgen Laws, Arndt Borkhardt, Roland Meisel.   

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has not been a therapeutic option in ataxia telangiectasia (AT) due to overwhelming toxicity of conditioning in the context of the global DNA repair deficiency. Furthermore HSCT is unable to cure neurological involvement of AT. We report on a Turkish child with a Hyper IgM phenotype disorder, in which clinical aspects of AT were absent and thus, AT not diagnosed. He was transplanted with a reduced toxicity, but full intensity conditioning regimen comprising treosulfan, fludarabine and ATG. The peritransplant period was uneventful and the patient was discharged at day +57. 8 months after HSCT, the patient developed hepatopathy with monoclonal gammopathy of unclear significance and died due to hepatic failure and encephalopathy at the age of 32 months. Post mortem high throughput sequencing revealed a mutation in the ATM gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354567     DOI: 10.1007/s10875-012-9654-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  11 in total

1.  Bone marrow and thymus transplantation in ataxia-telangiectasia.

Authors:  R H Buckley
Journal:  Birth Defects Orig Artic Ser       Date:  1975

2.  Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Naynesh R Kamani; Shimareet Kumar; Anna Hassebroek; Mary Eapen; Jennifer LeRademacher; James Casper; Morton Cowan; José Sánchez de Toledo; Alina Ferster; Paul Szabolcs; John R Wingard; Edwin Horwitz; Alexandra H Filipovich
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-20       Impact factor: 5.742

3.  Hepatic veno-occlusive disease in ataxia-telangiectasia.

Authors:  N Srisirirojanakorn; M J Finegold; G S Gopalakrishna; W J Klish
Journal:  J Pediatr       Date:  1999-06       Impact factor: 4.406

Review 4.  Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

Authors:  Andrew M Evens; Rupali Roy; Danielle Sterrenberg; Michelle Z Moll; Amy Chadburn; Leo I Gordon
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

5.  Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

Authors:  Mary A Slatter; Kanchan Rao; Persis Amrolia; Terry Flood; Mario Abinun; Sophie Hambleton; Zohreh Nademi; Nick Goulden; Graham Davies; Waseem Qasim; Hubert B Gaspar; Andrew Cant; Andrew R Gennery; Paul Veys
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

6.  Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome.

Authors:  A Aghamohammadi; K Imai; K Moazzami; H Abolhassani; M Tabatabaeiyan; N Parvaneh; R Nasiri Kalmarzi; N Nakagawa; K Oshima; O Ohara; S Nonoyama; N Rezaei
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

7.  Ataxia-telangiectasia with hyper-IgM and Wilms tumor: fatal reaction to irradiation.

Authors:  Barbara Maria Pietrucha; Edyta Heropolitańska-Pliszka; Anna Wakulińska; Hanna Skopczyńska; Richard A Gatti; Ewa Bernatowska
Journal:  J Pediatr Hematol Oncol       Date:  2010-01       Impact factor: 1.289

8.  Ataxia-telangiectasia patients presenting with hyper-IgM syndrome.

Authors:  J G Noordzij; N M Wulffraat; A Haraldsson; I Meyts; L J van't Veer; F B L Hogervorst; A Warris; C M R Weemaes
Journal:  Arch Dis Child       Date:  2009-02-17       Impact factor: 3.791

9.  Immunodeficiency and infections in ataxia-telangiectasia.

Authors:  Anna Nowak-Wegrzyn; Thomas O Crawford; Jerry A Winkelstein; Kathryn A Carson; Howard M Lederman
Journal:  J Pediatr       Date:  2004-04       Impact factor: 4.406

10.  Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice.

Authors:  Jessamyn Bagley; Maria L Cortes; Xandra O Breakefield; John Iacomini
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

View more
  9 in total

1.  Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice.

Authors:  J Pietzner; B M Merscher; P C Baer; R P Duecker; O Eickmeier; D Fußbroich; P Bader; D Del Turco; R Henschler; S Zielen; R Schubert
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

2.  Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma.

Authors:  R Beier; K-W Sykora; W Woessmann; B Maecker-Kolhoff; M Sauer; H H Kreipe; T Dörk-Bousset; C Kratz; M Lauten
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

3.  Utility of DNA, RNA, Protein, and Functional Approaches to Solve Cryptic Immunodeficiencies.

Authors:  Margot A Cousin; Matthew J Smith; Ashley N Sigafoos; Jay J Jin; Marine I Murphree; Nicole J Boczek; Patrick R Blackburn; Gavin R Oliver; Ross A Aleff; Karl J Clark; Eric D Wieben; Avni Y Joshi; Pavel N Pichurin; Roshini S Abraham; Eric W Klee
Journal:  J Clin Immunol       Date:  2018-04-18       Impact factor: 8.317

4.  Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.

Authors:  James Slack; Michael H Albert; Dmitry Balashov; Bernd H Belohradsky; Alice Bertaina; Jack Bleesing; Claire Booth; Jochen Buechner; Rebecca H Buckley; Marie Ouachée-Chardin; Elena Deripapa; Katarzyna Drabko; Mary Eapen; Tobias Feuchtinger; Andrea Finocchi; H Bobby Gaspar; Sujal Ghosh; Alfred Gillio; Luis I Gonzalez-Granado; Eyal Grunebaum; Tayfun Güngör; Carsten Heilmann; Merja Helminen; Kohei Higuchi; Kohsuke Imai; Krzysztof Kalwak; Nubuo Kanazawa; Gülsün Karasu; Zeynep Y Kucuk; Alexandra Laberko; Andrzej Lange; Nizar Mahlaoui; Roland Meisel; D Moshous; Hideki Muramatsu; Suhag Parikh; Srdjan Pasic; Irene Schmid; Catharina Schuetz; Ansgar Schulz; Kirk R Schultz; Peter J Shaw; Mary A Slatter; Karl-Walter Sykora; Shinobu Tamura; Mervi Taskinen; Angela Wawer; Beata Wolska-Kuśnierz; Morton J Cowan; Alain Fischer; Andrew R Gennery
Journal:  J Allergy Clin Immunol       Date:  2017-04-07       Impact factor: 10.793

Review 5.  Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia.

Authors:  Shahrzad Bakhtiar; Sandra Woelke; Sabine Huenecke; Matthias Kieslich; Alexander Malcolm Taylor; Ralf Schubert; Stefan Zielen; Peter Bader
Journal:  Front Immunol       Date:  2018-10-29       Impact factor: 7.561

6.  Vasculitis in a Child With the Hyper-IgM Variant of Ataxia-Telangiectasia.

Authors:  Anna K Meyer; Mindy Banks; Tibor Nadasdy; Jennifer J Clark; Rui Zheng; Erwin W Gelfand; Jordan K Abbott
Journal:  Front Pediatr       Date:  2019-10-24       Impact factor: 3.418

7.  Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia.

Authors:  Ruth Duecker; Patrick C Baer; Aileen Buecker; Sabine Huenecke; Lisa-Marie Pfeffermann; Ute Modlich; Shahrzad Bakhtiar; Peter Bader; Stefan Zielen; Ralf Schubert
Journal:  Front Immunol       Date:  2019-11-27       Impact factor: 7.561

8.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

9.  Atm reactivation reverses ataxia telangiectasia phenotypes in vivo.

Authors:  Sara Di Siena; Federica Campolo; Roberto Gimmelli; Chiara Di Pietro; Daniela Marazziti; Susanna Dolci; Andrea Lenzi; Andre Nussenzweig; Manuela Pellegrini
Journal:  Cell Death Dis       Date:  2018-02-22       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.